AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS for AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Issues related to drug pricing, drug shortages, drug importation plans, and the drug supply chain, including support for the Mapping Americas Pharmaceutical Supply (MAPS) Act (S. 1784/S. Amdt. 3753). Issues related to telehealth and pharmacist provision of testing and vaccination (generally, no specific legislation). Patient access to pharmacist provided services for respiratory illnesses, initiation of oral antivirals, buprenorphine, and other pharmacist services authorized under state law (generally, no specific legislation). Issues related to healthcare workforce shortages (generally, no specific legislation). Provisions related to site neutral payments (generally, no specific legislation). The Dr. Lorna Breen Health Care Provider Protection Reauthorization Act (H.R. 929/S. 266), provisions related to supporting health workers mental health and well-being. Issues related to implementation of the Inflation Reduction Act (generally, no specific legislation). Issues related to protecting federal student loan programs, including the Grad PLUS program (generally, no specific legislation). Issues related to direct-to-consumer (DTC) prescription drug advertising (generally, no specific legislation). Issues related to vaccine access and evidence-based resources for patients and pharmacists (generally, no specific legislation).
| Lobbyist | Covered position, as disclosed |
|---|---|
| FRANK KOLB New | — |
| THOMAS KRAUS | — |
| JILLANNE SCHULTE | — |
Medicare/Medicaid MMM
The Ensuring Community Access to Pharmacist Services Act (H.R. 3164/S. 2426), including reimbursement for pharmacist provision of testing and vaccination. Issues related to telehealth reimbursement and virtual supervision flexibilities for pharmacist services with CMS (generally, no specific legislation). Issues related to extension of site-neutral policies to drug administration services in hospital provider-based departments (generally, no specific legislation). Issues related to implementation of Medicare drug price negotiation (generally, no specific legislation).
| Lobbyist | Covered position, as disclosed |
|---|---|
| FRANK KOLB New | — |
| THOMAS KRAUS | — |
| JILLANNE SCHULTE | — |
Pharmacy PHA
The Rebuild Americas Health Care Schools Act (H.R. 1708/S. 1087), issues related to pharmacy residency funding. Issues related to FDA authority to manage drug shortages, regulation of pharmacy compounding, and implementation of the Drug Quality and Security Act. The Biosimilar Red Tape Elimination Act (S. 1954), issues related to increased patient access to essential biosimilar medications. Issues related to pharmacy benefit manager (PBM) abuses and transparency (generally, no specific legislation). The 340B PATIENTS Act (H.R. 4581/S. 2372), issues related to 340B program nondiscrimination and contract pharmacy arrangements. Issues related to manufacturer attempts to undercut the 340B program, including conversion of the program to a rebate model (generally, no specific legislation). Issues related to drug price negotiations and patient out-of-pocket costs (generally, no specific legislation).
| Lobbyist | Covered position, as disclosed |
|---|---|
| FRANK KOLB New | — |
| THOMAS KRAUS | — |
| JILLANNE SCHULTE | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.